KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Change in Receivables (2016 - 2025)

Gilead Sciences' Change in Receivables history spans 17 years, with the latest figure at -$179.0 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 148.61% year-over-year to -$179.0 million; the TTM value through Dec 2025 reached $367.0 million, up 364.03%, while the annual FY2025 figure was $367.0 million, 364.03% up from the prior year.
  • Change in Receivables reached -$179.0 million in Q4 2025 per GILD's latest filing, down from $333.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $612.0 million in Q3 2023 to a low of -$975.0 million in Q1 2021.
  • Average Change in Receivables over 5 years is $8.2 million, with a median of $47.5 million recorded in 2024.
  • Peak YoY movement for Change in Receivables: crashed 359.31% in 2021, then surged 906.9% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$41.0 million in 2021, then surged by 785.37% to $281.0 million in 2022, then crashed by 178.29% to -$220.0 million in 2023, then skyrocketed by 67.27% to -$72.0 million in 2024, then plummeted by 148.61% to -$179.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's Change in Receivables are -$179.0 million (Q4 2025), $333.0 million (Q3 2025), and $292.0 million (Q2 2025).